Gemtesa is THE FIRST AND ONLY
BETA-3 AGONIST THAT DOES NOT
CAUSE CYP2D6 DRUG INTERACTIONS1

79.3%

79.3% of patients taking any overactive bladder (OAB) medication also take medicine metabolized through the CYP2D6 pathway2*

OAB patients take an average of 12–14 medications annually,† many of which are metabolized by CYP2D62-4

Common comorbidities in patients with OAB include:

  • Hypertension
  • Depression
  • Diabetes

Regularly prescribed medications that are metabolized by CYP2D64-7

SSRIs/SNRI

  • Fluoxetine
  • Duloxetine
  • Paroxetine

BETA-BLOCKERS

  • Metoprolol
  • Carvedilol
  • Propranolol

TRICYCLIC
ANTIDEPRESSANTS

  • Amitriptyline
  • Nortriptyline
  • Doxepin

ATYPICAL
ANTIPSYCHOTICS

  • Aripiprazole
  • Risperidone
  • Olanzapine

GEMTESA has not been studied in concomitant use with these medications.

Digoxin drug interaction was identified with GEMTESA. Measure serum digoxin concentrations before initiating GEMTESA. Monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. Continue monitoring digoxin concentrations upon discontinuation of GEMTESA and adjust digoxin dose as needed.1

*Data from IQVIA PharMetrics® Plus (Pharmetrics) between November 2012-September 2019 that evaluated adult patients taking a medication for OAB (N=838,844) and subsequently prescribed any prespecified CYP2D6 substrate (n=106).2

†Data from 2 studies. The first study examined patients (65.4% were ≥75 years old) with OAB who had concurrent medical conditions and received concomitant medications (n=415). The second study analyzed the number of OAB medications taken by patients ≥65 years old during a more than 1-year period (n=1,801,457).2,3

CYP2D6=cytochrome P450 2D6; SNRI=serotonin-norepinephrine reuptake inhibitor; SSRI=selective serotonin reuptake inhibitor.

Learn more about GEMTESA, a selective beta-3 adrenergic agonist

See MOA
 

References: 1. GEMTESA. Prescribing Information. Marlborough, MA; Sumitomo Pharma America; 2023. 2. Data on file. Sumitomo Pharma America, Inc. 3. Ganz ML, Liu J, Zou KH, Bhagnani T, Luo X. Real-world characteristics of elderly patients with overactive bladder in the United States. Curr Med Res Opin. 2016;32(12):1997-2005. doi:10.1080/03007995.2016.1226167 4. Hansten PD, Horn JR. The Top 100 Drug Interactions: A Guide to Patient Management. 2019 ed. Freeland, WA: H&H Publications, LLP; 2019. 5. Kane SP. Drug List by Therapeutic Category. ClinCalc.com. Accessed March 28, 2023. https://clincalc.com/Downloads/Top250Drugs-DrugList.pdf 6. Kane SP. Doxepin. ClinCalc.com. Accessed January 18, 2023. https://clincalc.com/DrugStats/Drugs/Doxepin 7. Kane SP. Tricyclic Antidepressants. ClinCalc.com. Accessed April 4, 2023. https://clincalc.com/DrugStats/TC/TricyclicAntidepressants

Back to Top